Guillaume Thoviste

CorFlow was founded on the belief that current PCI and cardiac care remains suboptimal due the fact that underlying microvascular dysfunction and obstruction is not detected and treated adequately. CorFlow believes, like much of the medical community, that the next frontier of innovation and positive impact on clinical outcomes in cardiology and beyond will come from the microvascular space. Our first solution is a system that will be the first to diagnose microvascular obstruction (MVO) in real time during PCI and serve as a treatment platform in the cath lab. There are ongoing clinical studies to demonstrate safety and efficacy so the platform remains investigational use only. Our Mission - To extend and improve the quality of human life with a relentless pursuit to solve unmet medical needs Our Vision - To be the leader in diagnostic and therapeutic solutions for restoring healthy microvascular blood flow anywhere in the human body where a critical need exists Our Values - To place quality above all else - To treat all people with the highest moral and ethical standards - To be a fair partner to everyone we work with and serve - To foster inclusion, transparency, well-being and positivity with our employees while chasing ambitious goals - To embrace a holistic view of success, inclusive of environmental, social and governance targets we hold ourselves accountable for CorFlow was founded in 2016 in Baar, Switzerland and now has offices in both Baar and Bern, Switzerland. The company has been financed by a combination of seed funding by angel investors, Venture Capital, and grants via a partnership with the Swiss government that awards significant innovation to improve health care. The Series A financing round closed in 2021, and a Series B round is targeted for 2023. Our CEO is Paul Mead, who brings close to 20 years of operational experience in medtech working for Medtronic. The Chairman of our Board is Rick Geoffrion, CEO of Cyrano Therapeutics.

Broken String Biosciences is a genomics company that is building a technology platform to drive the development of cell & gene therapies that are safer by design.

Providing genomic analysis to everybody. SeqOne is a company focused on developing state-of-the-art genomic analysis tools for clinical applications in the fields of cancer and rare disease. The companys vision is to develop a genomic analysis system that dramatically reduces the cost and resources needed to provide accurate genomic analysis. Our aim is to make genetic testing easier and more accessible in order to accelerate the adoption of personalized medicine. SeqOne’s platform makes it possible to efficiently analyze "high resolution" next generation sequencing (NGS) data, providing a complete list of all genetic variants and prioritizing them in order of relevance. The platform uses a proprietary machine learning-based variant prioritization engine designed to identify variants that are medically relevant to each specific patient. SeqOne bioinformatics (genomic analysis algorithms) are organized by applications, which provide accurate answers to medical questions that influence patient treatment, in both constitutional and somatic pathologies. SeqOne offers applications to analyze a single-patient or an entire family to diagnose hereditary family disorders, detecting complex events such as large structural modifications or transposable elements. In the field of somatic cancer, applications can analyze tumor-only, compare healthy versus tumoral samples, or hematological cancers identifying relevant variants, such as somatic CNV, TMB, MSI, or fusion genes, as well as suggest therapeutic options. The SeqOne platform addresses the operational challenges of performing NGS analysis at scale, including secure data storage, management of process quality, and traceability needed for certification. We adopt a unique approach to process quality control that addresses ongoing process monitoring as well as changes to upstream lab procedures.

CAIRDAC is developing a new autonomous leadless pacing transcatheter system incorporating a revolutionary energy harvesting module capable of powering the device with no battery-life limitation. Our new architecture of autonomous leadless pacing system will bring CRM disciplines at a paradigm shift in overcoming inherent drawbacks of current products.

PhysioAssist est une société de matériel médical qui a développé une expertise en rhéologie, étude de la physique du mucus bronchique. Après plusieurs années de recherches, un signal vibratoire pneumatique efficace a été caractérisé pour agir sur le mucus intra pulmonaire, le liquéfier et le drainer. Ce signal est délivré par le dispositif médical Simeox, qui stimule le mucus bronchique par dépressions successives, tout en assurant une expiration passive. Simeox est destiné aux patients atteints de pathologies respiratoires chroniques.

CorFlow was founded on the belief that current PCI and cardiac care remains suboptimal due the fact that underlying microvascular dysfunction and obstruction is not detected and treated adequately. CorFlow believes, like much of the medical community, that the next frontier of innovation and positive impact on clinical outcomes in cardiology and beyond will come from the microvascular space. Our first solution is a system that will be the first to diagnose microvascular obstruction (MVO) in real time during PCI and serve as a treatment platform in the cath lab. There are ongoing clinical studies to demonstrate safety and efficacy so the platform remains investigational use only. Our Mission - To extend and improve the quality of human life with a relentless pursuit to solve unmet medical needs Our Vision - To be the leader in diagnostic and therapeutic solutions for restoring healthy microvascular blood flow anywhere in the human body where a critical need exists Our Values - To place quality above all else - To treat all people with the highest moral and ethical standards - To be a fair partner to everyone we work with and serve - To foster inclusion, transparency, well-being and positivity with our employees while chasing ambitious goals - To embrace a holistic view of success, inclusive of environmental, social and governance targets we hold ourselves accountable for CorFlow was founded in 2016 in Baar, Switzerland and now has offices in both Baar and Bern, Switzerland. The company has been financed by a combination of seed funding by angel investors, Venture Capital, and grants via a partnership with the Swiss government that awards significant innovation to improve health care. The Series A financing round closed in 2021, and a Series B round is targeted for 2023. Our CEO is Paul Mead, who brings close to 20 years of operational experience in medtech working for Medtronic. The Chairman of our Board is Rick Geoffrion, CEO of Cyrano Therapeutics.

Broken String Biosciences is a genomics company that is building a technology platform to drive the development of cell & gene therapies that are safer by design.

Providing genomic analysis to everybody. SeqOne is a company focused on developing state-of-the-art genomic analysis tools for clinical applications in the fields of cancer and rare disease. The companys vision is to develop a genomic analysis system that dramatically reduces the cost and resources needed to provide accurate genomic analysis. Our aim is to make genetic testing easier and more accessible in order to accelerate the adoption of personalized medicine. SeqOne’s platform makes it possible to efficiently analyze "high resolution" next generation sequencing (NGS) data, providing a complete list of all genetic variants and prioritizing them in order of relevance. The platform uses a proprietary machine learning-based variant prioritization engine designed to identify variants that are medically relevant to each specific patient. SeqOne bioinformatics (genomic analysis algorithms) are organized by applications, which provide accurate answers to medical questions that influence patient treatment, in both constitutional and somatic pathologies. SeqOne offers applications to analyze a single-patient or an entire family to diagnose hereditary family disorders, detecting complex events such as large structural modifications or transposable elements. In the field of somatic cancer, applications can analyze tumor-only, compare healthy versus tumoral samples, or hematological cancers identifying relevant variants, such as somatic CNV, TMB, MSI, or fusion genes, as well as suggest therapeutic options. The SeqOne platform addresses the operational challenges of performing NGS analysis at scale, including secure data storage, management of process quality, and traceability needed for certification. We adopt a unique approach to process quality control that addresses ongoing process monitoring as well as changes to upstream lab procedures.

CAIRDAC is developing a new autonomous leadless pacing transcatheter system incorporating a revolutionary energy harvesting module capable of powering the device with no battery-life limitation. Our new architecture of autonomous leadless pacing system will bring CRM disciplines at a paradigm shift in overcoming inherent drawbacks of current products.

Merieux Equity Partners is a multistage investment manager specialized in the healthcare & nutrition sectors via two dedicated platforms: Venture and Growth/Buyout. As an independent General Partner - registered under the French Financial Markets Authority AMF ("Autorité des Marchés Financiers") - Merieux Equity Partners currently manages 5 main funds, representing more than €1 billion of Commitments, and has supported over 45 companies in Europe and North America since its creation - in Venture Capital and Growth/Buyout. Our passion is to work alongside entrepreneurs and companies with an ambitious growth plan, offering them privileged access to our sector-expertise and cross-border experience. With a team of 24 full-time employees and 6 Senior Advisors, we strive to bring the best of our operational experience and privileged access to Merieux industrial network.